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ABSTRACT
Objective: To evaluate the efficacy of combined oral medroxyprogesterone acetate (MPA)/
levonorgestrel-intrauterine system (LNG-IUS) treatment and to compare the diagnostic 
accuracy of endometrial aspiration biopsy with dilatation & curettage (D&C) in young women 
with early-stage endometrial cancer (EC) who wished to preserve their fertility.
Methods: A prospective phase II multicenter study was conducted from January 2012 
to January 2017. Patients with grade 1 endometrioid adenocarcinoma confined to the 
endometrium were treated with combined oral MPA (500 mg/day)/LNG-IUS. At 3 and 6 
months of treatment, the histologic change of the endometrial tissue was assessed. The 
regression rate at 6 months treatment and the consistency of the histologic results between 
the aspiration biopsy and the D&C were evaluated.
Results: Forty-four patients were enrolled. Nine voluntarily withdrew and 35 patients 
completed the protocol treatment. The complete regression (CR) rate at 6 months was 
37.1% (13/35). Partial response was shown in 25.7% of cases (9/35). There were no cases of 
progressive disease and no treatment-related complications. A comparison of the pathologic 
results from aspiration biopsy and D&C was carried out for 33 cases. Fifteen cases were 
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diagnosed as “EC” by D&C. Among these, only 8 were diagnosed with EC from aspiration 
biopsy, yielding a diagnostic concordance of 53.3% (ĸ=0.55).
Conclusion: Combined oral MPA/LNG-IUS treatment for EC showed 37.1% of CR rate at 
6 months. Considering the short treatment periods, CR rate may be much higher if the 
treatment continued to 9 or 12 months. So, this treatment is still a viable treatment option for 
young women of early-stage EC. Endometrial aspiration biopsy with the LNG-IUS in place is 
less accurate than D&C for follow-up evaluation of patients undergoing this treatment.
Trial Registration: ClinicalTrials.gov Identifier: NCT01594879
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INTRODUCTION
Endometrial cancer (EC) is the most common gynecologic malignancy in developed 
countries. Although it is generally diagnosed in postmenopausal women, 3%–14% of cases 
occur in those younger than 40 years of age. Recently in Korea, the overall incidence of 
EC increased by 6.9% per year. Especially, EC in the young age group (age <30 years), who 
are frequently nulliparous and have a strong desire to preserve fertility at the time of their 
diagnosis, has increased by 11.2% per year [1-3].
EC in the young age group is usually well-differentiated endometrioid adenocarcinoma with 
infrequent myometrial invasion or lymph node metastasis. Therefore, it tends to show a favorable 
prognosis [4,5]. When EC is diagnosed in young patients wishing to preserve their fertility, the 
standard surgical treatment proceeding by hysterectomy and bilateral salpingo-oophorectomy 
may not be ideal. Moreover, given the increasing incidence of EC in younger patients, conservative 
management that preserves fertility has drawn attention and increasingly been investigated.
Current fertility-sparing treatment modalities are based on hormonal therapy, mainly with 
oral progestin. A number of studies have suggested that in selected patients with early-stage 
disease, EC can be effectively managed with oral progestin [6-16]. Additionally, other options 
have been investigated, including the use of the levonorgestrel-intrauterine system (LNG-
IUS) or gonadotropin-releasing hormone [17-22].
In recent pilot and observational studies, combined medroxyprogesterone acetate (MPA) and 
LNG-IUS treatment in patients with stage IA (confined to endometrium), grade 1 EC showed 
promising results [19,22]. However, there has been no prospective trial on the effectiveness 
of combined oral MPA/LNG-IUS treatment. Furthermore, there is still no reliable data on 
the proper surveillance method during hormonal treatment of EC, especially when using 
the LNG-IUS. When using the LNG-IUS, the endometrial response could be evaluated by 
endometrial aspiration biopsy with the LNG-IUS in the uterus or by dilatation and curettage 
(D&C) after removal of the LNG-IUS. Notwithstanding, there has been no report on any 
comparison of these methods' accuracies.
Therefore, we designed a large phase II multicenter prospective study to evaluate the efficacy 
of combined oral MPA/LNG-IUS treatment in young women with early-stage EC who wish 
to preserve their fertility and to compare the diagnostic accuracy of endometrial aspiration 
biopsy with that of D&C in those patients.
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MATERIALS AND METHODS
1. Study design
A prospective phase II multicenter study was conducted from January 2012 to January 
2017. Thirteen institutions belonging to the Korean Gynecologic-Oncology Group were 
registered. Eligible subjects were women with histologically confirmed grade 1 endometrioid 
adenocarcinoma assumed to be FIGO Stage IA without myometrial invasion, who desired 
to preserve fertility and who were aged ≤40 years. The initial histologic diagnosis was 
made by D&C with the patient anesthetized. The clinical stage was assessed by transvaginal 
ultrasonography (TVS), abdomen-pelvic computed tomography (CT) and magnetic resonance 
imaging (MRI). No radiologic evidence of myometrial invasion, lymph node involvement or 
any extrauterine lesions were confirmed. All of the patients were fully informed of the study 
purposes and procedures, and their voluntary informed consent to participate (as approved 
by the institutional review board of each clinical trial institution) was obtained. This trial was 
registered at ClinicalTrials.gov (NCT01594879) and published in October 2012 [23].
2. Treatment and follow-up
Patients were treated with combined oral MPA (500 mg/day)/LNG-IUS. The follow-up 
schedule consisted of regular clinic review, transvaginal ultrasonography, and endometrial 
histological surveillance at 3-month intervals.
3. Evaluation of response
At 3 and 6 months of treatment, the histologic change of endometrial tissue was assessed 
via 2 methods: endometrial aspiration biopsy using a pipelle with the LNG-IUS remaining in 
the uterus, followed by D&C after removal of the LNG-IUS. The histologic diagnoses of the 
specimens were made by central pathologic review.
The treatment response was classified as follows: complete regression (CR), absence of any 
hyperplastic or cancerous lesion; partial response (PR), presence of residual hyperplasia or 
carcinoma with degeneration or atrophy of endometrial glands; no change (NC), presence of 
residual lesion without degeneration or atrophy of endometrial glands; progressive disease 
(PD), progression to higher-grade lesion or clinically progressive disease. At the 3-month 
treatment evaluation, patients with CR, PR or NC continued with the MPA (500 mg/day)/
LNG-IUS treatment for an additional 3 months. If there was histological evidence of PD, the 
protocol treatment was stopped, and surgical treatment was suggested (Fig. 1).
4. Outcome measure
The primary outcome was the response rate at 6 months of treatment. This was determined 
by comparing the diagnosis of the follow-up D&C 6 months after MPA/LNG-IUS treatment 
with the initial histologic diagnosis. The secondary outcome was the consistency of the 
results between the endometrial aspiration biopsy and the D&C. At 3 and 6 months of 
treatment, we obtained endometrial tissues via the two methods noted above. To evaluate the 
diagnostic accuracy of the endometrial aspiration biopsy (with the LNG-IUS in the uterus) as 
compared with the D&C (after removal of the LNG-IUS), the histological results of the two 
methods were compared.
5. Sample size calculation and statistical considerations
This study was a single-arm phase II study with historical comparison. The primary endpoint 
was CR rate at 6 months of treatment. The historical control benchmark was a study by 
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Ushijima et al. [12]. They had administered 600 mg of MPA and found CR in 55% of patients. 
With a 5% one-sided Type I error, we calculated that a total of 35 patients would provide 
80% power in detecting of a 20% increase in CR rate. Assuming a 20% of dropouts or 
withdrawals, a total of 44 patients were accrued to the trial.
The secondary endpoint was the consistency of the results between the endometrial 
aspiration biopsy and the D&C. Kappa statistics were used to assess the agreement of the 2 
methods. κ values <0 indicated no agreement, 0 to 0.20 slight, 0.21 to 0.40 fair, 0.41 to 0.60 
moderate, 0.61 to 0.80 substantial, and 0.81 to 1 almost perfect agreement.
RESULTS
A total of 44 patients meeting the inclusion criteria were enrolled. Nine patients voluntarily 
withdrew and 35 patients completed the protocol treatment (Fig. 2).
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PDCR, PR, NC
Removal from studyMPA 500 mg/day+LNG-IUS
D&C after aspiration biopsy
EC Ia G1
MPA 500 mg/day+LNG-IUS
D&C after aspiration biopsy✓ At 3 months
✓ At 6 months,
final evaluation
Fig. 1. Study design. 
CR, complete response (defined as absence of any hyperplastic or cancerous lesion); D&C, dilation and 
curettage; EC, endometrial carcinoma; G1, grade 1; LNG-IUS, levonorgestrel-releasing intrauterine system; MPA, 
medroxyprogesterone acetate; NC, no change (defined as residual lesion without degeneration or atrophy of 
endometrial glands); PD, progressive disease (defined as appearance of grade 2 or 3 endometrial carcinoma);  
PR, partial response (defined as residual lesion with degeneration and atrophy of endometrial glands).
Patients enrolled
(n=44)
Follow-up at 3 months
(n=35)
Voluntarily withdrew
(n=9)
Follow-up at 6 months
(n=35)
Fig. 2. Flowchart of study population.
The patients' baseline characteristics are provided in Table 1. The mean age of the patients 
was 32.9±3.9 years (range, 27–40 years) and the mean body weight index (BMI) was 24.5±5.9 
kg/m2 (range, 15.1–37.5 kg/m2). Thirty-three (94.3%) patients were nulliparous.
At 6 months of treatment, the CR rate was 37.1% (13/35). PR was shown in 25.7% (9/35) and 
NC in 37.1% (13/35) of cases. There were no cases of PD (Table 2).
Of the 13 patients with CR at 6 months, 4 had already presented CR at 3 months. Seven 
patients with PR and 2 with NC at 3 months achieved CR after an additional 3 months 
of treatment (Fig. 3). Treatment generally was well tolerated, and there were no cases of 
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Table 1. Patients' characteristics (n=35)
Characteristics Values
Age (yr) 32.9±3.9 (27–40)
Body mass index (kg/m2) 24.5±5.9 (15.1–37.5)
Parity
0 33 (94.3%)
1 2 (5.7%)
Data are expressed as means±standard deviation or number.
Table 2. Response to combined MPA (500 mg/day)/LNG-IUS treatment (n=35)
Response 3 months 6 months
CR 11.4% (4/35) 37.1% (13/35)
PR 34.3% (12/35) 25.7% (9/35)
NC 54.3% (19/35) 37.1% (13/35)
PD 0% (0/35) 0% (0/35)
CR, complete response; LNG-IUS, levonorgestrel-intrauterine system; MPA, medroxyprogesterone acetate; NC, 
no change; PD, progressive disease; PR, partial response.
EC Ia G1
(n=35)
NC
(n=19)
PR
(n=12)
CR
(n=4)
PD
(n=0)
NC
(n=13)
PR
(n=9)
CR
(n=13)
PD
(n=0)
MPA 500 mg/day+LNG-IUS
n=4
n=7
At 3 months At 6 months
n=2
Fig. 3. Flowchart of treatment outcome. 
CR, complete response (defined as absence of any hyperplastic or cancerous lesion); EC, endometrial carcinoma; 
G1, grade 1; LNG-IUS, levonorgestrel-releasing intrauterine system; MPA, medroxyprogesterone acetate; NC, 
no change (defined as residual lesion without degeneration or atrophy of endometrial glands); PD, progressive 
disease (defined as appearance of grade 2 or 3 endometrial carcinoma); PR, partial response (defined as residual 
lesion with degeneration and atrophy of endometrial glands).
treatment-related complication. There were no correlations between treatment response and 
clinical characteristics including age and BMI.
Comparison of the pathologic results from aspiration biopsy and D&C was carried out for 
33 cases. The histologic results by D&C were 15 (45.4%) with EC, 12 (36.4%) with EH and 
6 (18.2%) with normal endometrium. Generally, 20 of 33 cases (60.6%) had diagnostic 
concordance, consisting of 4 cases potentially with normal endometrium, 8 cases with EC 
and 8 cases with EH. Among the 15 cases of EC on D&C, only 8 were diagnosed with EC from 
aspiration biopsy, yielding a diagnostic concordance of 53.3% (ĸ=0.55). Among the 9 cases of 
normal endometrium by aspiration biopsy, 3 were diagnosed as “EC,” and 2 as “EH” by D&C. 
There were 4 cases of “insufficient tissue for pathologic evaluation” histological results by 
aspiration biopsy. Among these 4 cases, 2 were diagnosed as “normal endometrium,” and the 
2 others were diagnosed as “EH” by D&C (Table 3).
DISCUSSION
Considering the recent rising incidence of EC in reproductive age women and their 
relatively good prognosis, it is imperative to provide them with an effective fertility-sparing 
treatment option. To date, there have been several promising results about progestin-
based conservative treatment for early-stage EC, the mainstay option being treatment with 
oral progestin [6-16]. In previous retrospective studies and case series, the response rate 
varied widely, ranging from 57% to 78%. These large variations were due to differences in 
treatment protocol, including differences in drugs used, dosage, and treatment duration. In 
2007, Ushijima et al. [12] reported the first results of a prospective multicenter study. They 
had administered 600 mg of MPA and low-dose aspirin daily for 26 weeks to 28 patients 
with stage I, grade 1 EC, and found CR in 55% of patients. This is relatively unsatisfactory, 
especially compared with the high cure rate (>93%) of surgical treatment. Therefore, a more 
effective treatment method with less adverse systemic effects was, and is still, sought.
In early-stage EC confined to the endometrium, LNG-IUS, which delivers a high 
concentration of progestin locally, can be an acceptable treatment option. According to 
a recent review, 17 of 37 patients with stage IA, grade 1 EC achieved CR with a LNG-IUS; 
the pooled complete response rate was 46% (95% confidence interval, 29%–63%) [21]. 
Moreover, some studies have investigated the combined use of LNG-IUS with oral progestin 
or gonadotropin-releasing hormone agonist to improve the treatment effect [19-25]. Based 
on a previous observational study, Kim et al. [22] reported promising results for 16 patients 
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Table 3. Comparison of pathologic results from endometrial aspiration biopsy and D&C
D&C No. (%) Aspiration biopsy No. Concordance to D&C (%)
Normal 6 (18.2) Normal 4 66.7
Material insufficiency 2
EC 15 (45.4) EC 8 53.3
EH 4
Normal 3
EH 12 (36.4) EH 8 66.6
Normal 2
Material insufficiency 2
Total 33 (100.0) 60.6
D&C: dilatation and curettage; EC, endometrial adenocarcinoma; EH, endometrial hyperplasia.
with stage IA, grade 1 EC who had been treated with combined oral MPA/LNG-IUS. The 
overall CR rate was 87.5% (14/16), and only 2 patients (14.3%) suffered recurrence.
Motivated by this result, we set out to conduct a multicenter prospective study to evaluate 
the efficacy of combined oral MPA/LNG-IUS treatment and a proper surveillance method. 
However, at 6 months follow-up, the CR rate was 37.1% (13/35), which is a somewhat 
disappointing outcome compared with those of previous studies. We considered that the 
relatively short treatment and follow-up periods could have been the culprits.
To date, the median treatment duration to CR and the total treatment duration have varied 
among studies, and there is no consensus on the optimal duration of treatment or when 
treatment failure should be determined. According to previous studies, most investigators 
recognize the need for a minimum of 3 months of treatment before assessment for a response 
[11,26]. Randall et al. reported that the median length of progestin treatment required for 
regression is 9 months; other studies have reported that patients achieved CR after 9–12 
months of treatment [6,7,15,16]. According to a previous report of combined oral MPA/LNG-
IUS treatment for early-stage EC, the median time to CR was 9.8±8.9 months (range, 3–35 
months) [22]. Further, a study that investigated the efficacy of combined oral MPA/LNG-IUS 
treatment for patients with stage IA, grade 2 EC reported that CR was shown in 3 of the 5 
patients, and that the median time to CR was 11.0±6.2 months (range, 6–18 months) [24]. In 
this regard, further investigation with longer treatment and follow-up periods is warranted. 
To the best of our knowledge, ours is the first multicenter prospective study to show the 
efficacy of combined oral MPA/LNG-IUS treatment in young women with early-stage EC who 
wish to preserve their fertility.
Another important issue that we wanted to investigate in this study is the proper surveillance 
method for EC patients treated with combined oral MPA/LNG-IUS: Can aspiration biopsy be 
as accurate as D&C as a follow-up evaluation method? The pathologic outcome at follow-up 
provides a basis for determining whether to continue conservative treatment of EC or not. 
Thus, the accuracy of the follow-up evaluation method is essential.
Although D&C is considered to be the most accurate method for diagnosis of EC, some 
studies have reported that aspiration biopsy seems to be as accurate as D&C [27]. However, 
these results were obtained for cases where there were no progestin effects on the 
endometrium and where the LNG-IUS was not in the uterus. Moreover, the evaluation of 
diagnostic accuracy focused on the initial diagnosis, not the follow-up evaluation, which can 
possibly be affected by hormonal treatment or LNG-IUS mechanical interference.
To date, there have been only 2 observational studies on the response of the endometrium 
in follow-up, particularly for EC patients treated with combined oral MPA/LNG-IUS [28,29]. 
In one study comparing the accuracy of aspiration biopsy (with the LNG-IUS in the uterus) 
with that of D&C (after LNG-IUS removal), the diagnostic concordance between the 2 
examinations was only 32.1% [28]. Another study compared the accuracy of aspiration biopsy 
with that of D&C after LNG-IUS removal to avoid mechanical interference of LNG-IUS, and 
the diagnostic concordance was 39.3% [29]. That is, the diagnostic accuracy of endometrial 
aspiration biopsy with or without the LNG-IUS in place has been found to be very poor. 
Furthermore, a high prevalence of insufficient tissue for pathologic evaluation was noted 
(46.7%–60.7%) with endometrial aspiration biopsy.
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We compared the diagnostic accuracy of endometrial aspiration biopsy with the LNG-IUS in 
the uterus versus D&C after removal of the LNG-IUS. Among the 15 cases of EC on D&C, only 
8 were diagnosed with EC from aspiration biopsy, yielding a diagnostic concordance of 53.3% 
(ĸ=0.55). These findings, significantly, are consistent with those of earlier studies.
These results can be considered to indicate that aspiration biopsy failed to obtain adequate 
amounts of tissue for diagnosis, due to endometrial atrophy induced by high-dose oral 
progestin and LNG-IUS, not to mention mechanical interference from the LNG-IUS. The 
clinical significance of this study is that it is the first prospective multicenter study to show 
that D&C is more accurate than aspiration biopsy in the evaluation of treatment response for 
combined oral MPA/LNG-IUS treatment.
In conclusion, the combined oral MPA/LNG-IUS treatment for EC showed 37.1% of CR rate 
at 6 months of follow-up. Considering the present study's short treatment and follow-up 
periods, CR rate may be much higher if the treatment continued to 9 or 12 months. So, this 
treatment is still a viable treatment option for young women of early-stage EC and a long-
term follow-up study will be valuable. It should also be noted that endometrial aspiration 
biopsy with LNG-IUS in place is less accurate than D&C after removal of LNG-IUS for follow-
up evaluation in patients with combined oral MPA/LNG-IUS treatment for EC. As accurate 
diagnosis and response assessment are essential to successful conservative treatment of EC, 
D&C after removal of LNG-IUS should be implemented as a surveillance method.
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